Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lymphoma, Mantle-Cell × Doxorubicin × Clear all

Phase

Phase 2 26 Phase 3 8 Phase 1/2 5 Phase 1 3 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Breast Neoplasms 3 Neoplasm, Residual 2 Wilms Tumor 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Rhabdomyosarcoma 1 Obesity 1 Non-Muscle Invasive Bladder Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Liver Neoplasms 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Body Weight 1

Interventions

Cyclophosphamide 2 prednylidene 1 ibrutinib 1 acalabrutinib 1 Vincristine 1 Thiotepa 1 Thalidomide 1 Rituximab 1 Radiotherapy 1 Prednisone 1 Filgrastim 1 Etoposide 1 Doxorubicin 1 Dexamethasone 1 Cytarabine 1 Cisplatin 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02858804 2026-02-11

BDH-MCL01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡